Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
190.2(c) 190.34(c) 183.46(c) 184.15(c) 182.21 Last
323 891 1 187 034 575 014 761 808 1 042 299 Volume
+1.45% +0.07% -3.61% +0.38% -1.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 856 M - -
Net income 2021 -749 M - -
Net cash position 2021 1 440 M - -
P/E ratio 2021 -28,7x
Yield 2021 -
Sales 2022 1 298 M - -
Net income 2022 -477 M - -
Net cash position 2022 1 274 M - -
P/E ratio 2022 -47,5x
Yield 2022 -
Capitalization 21 655 M 21 655 M -
EV / Sales 2021 23,6x
EV / Sales 2022 15,7x
Nbr of Employees 1 453
Free-Float 99,4%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic... 
Sector
Biotechnology & Medical Research
Calendar
09/28 | 10:40amPresentation
More about the company
Ratings of Alnylam Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALNYLAM PHARMACEUTICALS, INC.
09/13ALNYLAM PHARMACEUTICALS : Submits Marketing Authorization Application in the EU for Invest..
MT
09/13ALNYLAM PHARMACEUTICALS : Submits Marketing Authorization Application to the European Medi..
BU
09/13Alnylam Pharmaceuticals, Inc. Submits Marketing Authorization Application to European M..
CI
09/08ALNYLAM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/08Alnylam Pharmaceuticals, Inc. Announces Retirement of Laurie B. Keating as Executive Vi..
CI
09/07ALNYLAM PHARMACEUTICALS : Reports Additional Positive Data From Phase 3 Study of Vutrisira..
MT
09/07ALNYLAM PHARMACEUTICALS : Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of ..
BU
09/07Alnylam Pharmaceuticals, Inc. Presents Additional 9-Month Data from Helios-A Phase 3 St..
CI
09/07Alnylam Pharmaceuticals, Inc. Presents Additional 9-Month Data from HELIOS-A Phase 3 St..
CI
09/01ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming September Investor Conferen..
BU
08/31PRESS RELEASE : World-first agreement between -2-
DJ
08/27ALNYLAM PHARMACEUTICALS : BMO Capital Adjusts Price Target on Alnylam Pharmaceuticals to $..
MT
08/13ALNYLAM PHARMACEUTICALS : HC Wainwright Adjusts Alnylam Pharmaceuticals' Price Target to $..
MT
08/09ALNYLAM PHARMACEUTICALS : Completes Enrollment in Phase 3 Study of Vutrisiran
MT
08/09ALNYLAM PHARMACEUTICALS : Completes Enrollment in HELIOS-B Phase 3 Study of Investigationa..
BU
More news
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
09/07Alnylam Pharmaceuticals annonce des données positives supplémentaires sur l'étude de ph..
08/04Hoy en Wall Street: ┐Sigue en marcha la recuperación económica?
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
2020NOVARTIS : feu vert européen à l'anticholestérol Leqvio
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | ALNY | US02043Q1076 | MarketScreener
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 182,21 $
Average target price 182,85 $
Spread / Average Target 0,35%
EPS Revisions
Managers and Directors
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Jeffrey V. Poulton Chief Financial & Accounting Officer
Michael W. Bonney Executive Chairman
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.40.19%21 886
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.16%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021